News|Articles|March 17, 2025

CBT Isolate Launched by GVB Biopharma

GVB Biopharma announced their new CBT Isolate product.

In a recent press release, GVB Biopharma, a global distributor, developer, and manufacturer, discussed the launch of their new CBT Isolate product (1). As mentioned in the press release, it says, “CBT, also known as Cannabicitran, is a rare cannabinoid that is quickly emerging in the hemp and wellness industries. Like other rare cannabinoids, CBT demonstrates distinct properties and potential benefits for users seeking new functional product formulations.” The CBT Isolate is able to be used in a variety of products such as, edibles, tincture, topicals, and more.

Cannabicitran (CBT) is a cannabinoid that has been shown to have non-intoxicating properties and its benefits are being researched to see how the rare cannabinoid can be used to see how it can be used but has shown similar effects that are found in cannabidiol (CBD) and cannabigerol (CBG) (2,3).

“Our introduction of CBT Isolate underscores our dedication to leading the industry in both quality and innovation,” Drew Spiegel, CEO of GVB Biopharma said (1). “Rare cannabinoids are at the forefront of new product development, and GVB Biopharma strives to give our customers the best-in-class, high-purity ingredients they need to create differentiated and effective formulations.”

According to the press release, some of the key features and benefits of GVB Biopharma’s CBT Isolate are (1):

High Purity: Produced under stringent quality controls using state-of-the-art extraction and refinement processes.
Reliable Consistency: GVB Biopharma's certified manufacturing ensures uniform quality and potency with every batch.
Versatile Applications: Suitable for a wide range of product formats, including oils, beverages, supplements, and topicals.
Exceptional Quality Assurance: Backed by rigorous testing, transparent COAs, and expert support.

“In a rapidly evolving cannabinoid landscape, the introduction of CBT Isolate gives our clients the opportunity to remain on the cutting edge,” Jack Feldman, President of GVB Biopharma commented (1). “We're excited to see how brands will utilize CBT in their product development and how it will expand the possibilities of what cannabinoid formulations can offer.”

References